Surgical Endoscopy

, Volume 23, Issue 8, pp 1919–1921 | Cite as

Robotic D2 surgery for gastric cancer

  • H. Demetetriades
  • G. N. Marakis
  • D. Ziogas
  • I. Kanellos


  1. 1.
    Anderson C, Hellan M, Kernstine K, Ellenhorn J, Lai L, Trisal V, Pigazzi A (2007) Robotic surgery for gastrointestinal malignancies. Int J Med Robot 3(4):297–300PubMedGoogle Scholar
  2. 2.
    Ramirez PT, Soliman PT, Schmeler KM, dos Reis R, Frumovitz M (2008) Laparoscopic and robotic techniques for radical hysterectomy in patients with early-stage cervical cancer. Gynecol Oncol 110(3 Suppl 2):S21–S24PubMedCrossRefGoogle Scholar
  3. 3.
    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406PubMedCrossRefGoogle Scholar
  4. 4.
    McLeod R (2008) Long-term results of laparoscopic-assisted colectomy are comparable to results after open colectomy. Ann Surg 248(1):8–9PubMedCrossRefGoogle Scholar
  5. 5.
    Patriti A, Ceccarelli G, Bellochi R, Bartoli A, Spaziani A, Di Zitti L, Casciola L (2008) Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma. Surg Endosc, Sep 24 [Epub ahead of print]Google Scholar
  6. 6.
    Sasako M, Sano T, Yamamoto S, For Japan Clinical Oncology Group et al (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359(5):453–462PubMedCrossRefGoogle Scholar
  7. 7.
    Liakakos T, Roukos DH (2008) More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15(4):956–960PubMedCrossRefGoogle Scholar
  8. 8.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129PubMedCrossRefGoogle Scholar
  10. 10.
    Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695PubMedGoogle Scholar
  11. 11.
    Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221PubMedCrossRefGoogle Scholar
  12. 12.
    Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939PubMedCrossRefGoogle Scholar
  13. 13.
    Punglia RS, Morrow M, Winer EP et al (2007) Local therapy and survival in breast cancer. N Engl J Med 356:2399–2405PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721PubMedCrossRefGoogle Scholar
  15. 15.
    Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745PubMedCrossRefGoogle Scholar
  16. 16.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRefGoogle Scholar
  17. 17.
    Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med 357(3):283–291PubMedCrossRefGoogle Scholar
  18. 18.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715PubMedCrossRefGoogle Scholar
  19. 19.
    Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308–312PubMedCrossRefGoogle Scholar
  20. 20.
    Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4(10):578–590PubMedCrossRefGoogle Scholar
  21. 21.
    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(15):1555–1556 author reply 1556PubMedCrossRefGoogle Scholar
  22. 22.
    Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33PubMedCrossRefGoogle Scholar
  23. 23.
    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943PubMedGoogle Scholar
  24. 24.
    Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034PubMedCrossRefGoogle Scholar
  25. 25.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597PubMedCrossRefGoogle Scholar
  26. 26.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361PubMedCrossRefGoogle Scholar
  27. 27.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197 author reply 198PubMedCrossRefGoogle Scholar
  28. 28.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636 author reply 1636PubMedGoogle Scholar
  29. 29.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362–1363PubMedCrossRefGoogle Scholar
  30. 30.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798PubMedCrossRefGoogle Scholar
  31. 31.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773PubMedCrossRefGoogle Scholar
  32. 32.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392PubMedCrossRefGoogle Scholar
  33. 33.
    Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, casual networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • H. Demetetriades
    • 1
  • G. N. Marakis
    • 2
  • D. Ziogas
    • 3
  • I. Kanellos
    • 1
  1. 1.4th Department of SurgeryAristotle University of ThessalonikiThessalonikiGreece
  2. 2.Second Propedeutical Department of Surgery, Medical School, Hippocration HospitalAristotle UniversityThessalonikiGreece
  3. 3.Department of Surgery, School of MedicineUniversity of IoanninaIoanninaGreece

Personalised recommendations